PROTECT Me: RCT of Antenatal Melatonin Supplementation in Fetal Growth Restriction for Fetal Neuroprotection

Chief Investigators: Palmer, Miller, Fahey. CPA MRFF $498K.

Aims: Determine if antenatal maternal melatonin supplementation, improves neurodevelopmental outcomes at 2 years for survivors of fetal growth restriction (FGR) in 336 women with a singleton FGR pregnancy.

Mechanism: Antioxidant, anti-inflammatory and anti-apoptotic.

New Knowledge: First RCT of melatonin in FGR to assess neurodevelopment, n=258/300 recruited.

Project members

A/Professor Suzie Miller

Professor (Research), Obstetrics & Gynaecology Monash Health
Deputy Director of The Ritchie Centre at Monash University

Associate Professor Michael Fahey

Director of Neurogenetics, Monash Paediatrics
Monash University
Head of Child Neurology
Monash Children’s Hospital